241 related articles for article (PubMed ID: 20682393)
1. Number of somatic mutations in the mitochondrial D-loop region indicates poor prognosis in breast cancer, independent of TP53 mutation.
Kuo SJ; Chen M; Ma GC; Chen ST; Chang SP; Lin WY; Chen YC; Lee TH; Lin TT; Liu CS
Cancer Genet Cytogenet; 2010 Sep; 201(2):94-101. PubMed ID: 20682393
[TBL] [Abstract][Full Text] [Related]
2. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer.
Tseng LM; Yin PH; Chi CW; Hsu CY; Wu CW; Lee LM; Wei YH; Lee HC
Genes Chromosomes Cancer; 2006 Jul; 45(7):629-38. PubMed ID: 16568452
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
4. Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients.
Yu M; Zhou Y; Shi Y; Ning L; Yang Y; Wei X; Zhang N; Hao X; Niu R
IUBMB Life; 2007 Jul; 59(7):450-7. PubMed ID: 17654121
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
Zhu W; Qin W; Bradley P; Wessel A; Puckett CL; Sauter ER
Carcinogenesis; 2005 Jan; 26(1):145-52. PubMed ID: 15375011
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer.
Tan DJ; Bai RK; Wong LJ
Cancer Res; 2002 Feb; 62(4):972-6. PubMed ID: 11861366
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of mitochondrial mutations in colorectal cancer.
Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of the mitochondrial genome in human breast cancers.
Tseng LM; Yin PH; Yang CW; Tsai YF; Hsu CY; Chi CW; Lee HC
Genes Chromosomes Cancer; 2011 Oct; 50(10):800-11. PubMed ID: 21748819
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma.
Lee HC; Li SH; Lin JC; Wu CC; Yeh DC; Wei YH
Mutat Res; 2004 Mar; 547(1-2):71-8. PubMed ID: 15013701
[TBL] [Abstract][Full Text] [Related]
10. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
11. Methylation profile of TP53 regulatory pathway and mtDNA alterations in breast cancer patients lacking TP53 mutations.
Barekati Z; Radpour R; Kohler C; Zhang B; Toniolo P; Lenner P; Lv Q; Zheng H; Zhong XY
Hum Mol Genet; 2010 Aug; 19(15):2936-46. PubMed ID: 20466735
[TBL] [Abstract][Full Text] [Related]
12. A study of mitochondrial DNA D-loop mutations and p53 status in nonmelanoma skin cancer.
Prior SL; Griffiths AP; Lewis PD
Br J Dermatol; 2009 Nov; 161(5):1067-71. PubMed ID: 19624548
[TBL] [Abstract][Full Text] [Related]
13. Correlation between clinical characteristics and mitochondrial D-loop DNA mutations in hepatocellular carcinoma.
Tamori A; Nishiguchi S; Nishikawa M; Kubo S; Koh N; Hirohashi K; Shiomi S; Inoue M
J Gastroenterol; 2004 Nov; 39(11):1063-8. PubMed ID: 15580399
[TBL] [Abstract][Full Text] [Related]
14. Prediction of breast cancer prognosis by gene expression profile of TP53 status.
Takahashi S; Moriya T; Ishida T; Shibata H; Sasano H; Ohuchi N; Ishioka C
Cancer Sci; 2008 Feb; 99(2):324-32. PubMed ID: 18271932
[TBL] [Abstract][Full Text] [Related]
15. Mutations of mitochondrial DNA as potential biomarkers in breast cancer.
Cai FF; Kohler C; Zhang B; Chen WJ; Barekati Z; Garritsen HS; Lenner P; Toniolo P; Zhang JJ; Zhong XY
Anticancer Res; 2011 Dec; 31(12):4267-71. PubMed ID: 22199290
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA D-loop in pancreatic cancer: somatic mutations are epiphenomena while the germline 16519 T variant worsens metabolism and outcome.
Navaglia F; Basso D; Fogar P; Sperti C; Greco E; Zambon CF; Stranges A; Falda A; Pizzi S; Parenti A; Pedrazzoli S; Plebani M
Am J Clin Pathol; 2006 Oct; 126(4):593-601. PubMed ID: 16938655
[TBL] [Abstract][Full Text] [Related]
17. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
18. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
19. P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression.
de Jong KP; Gouw AS; Peeters PM; Bulthuis M; Menkema L; Porte RJ; Slooff MJ; van Goor H; van den Berg A
Clin Cancer Res; 2005 Jun; 11(11):4067-73. PubMed ID: 15930341
[TBL] [Abstract][Full Text] [Related]
20. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
